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1. Introduction
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes
is a series of editorials which is published on a biannual basis by the Editorial Board of the Medicinal
Chemistry section of the journal Molecules. In these editorials, we highlight in brief reports (of about
one hundred words) a number of recently published articles that describe crucial findings, such as the
discovery of novel drug targets and mechanisms of action or novel classes of drugs, which may inspire
future medicinal chemistry endeavors devoted to addressing prime unmet medical needs.
2. Targeting MAO Isoforms by cis/trans Isomers
Highlighted by Michael Gütschow
Human monoamine oxidases (hMAO) A and B, two therapeutically relevant isoforms for
central nervous disorders, share 70% sequence identity and are distinguished by different substrate
specificities and inhibitor sensitivities. The groups of Stanislav Gobec (Faculty of Pharmacy, University
of Ljubljana, Slovenia), Mariel Marder (Facultad de Farmacia y Bioquimica, Universidad de Buenos
Aires, Argentina) and Claudia Binder (Department of Biology and Biotechnology, University of
Pavia, Italy) have discovered the first example of hMAO-A and hMAO-B inhibitor pairs
(1-propargyl-4-styrylpiperidines) whose selectivity is conferred by the configurational cis/trans
isomerism [1]. Thus, the authors provided an impressive example of cis and trans isomers with
different pharmacological activities resulting from a discrimination between structurally related
enzyme isoforms. An expanded library of test compounds synthesized, and enzyme inhibition was
investigated by kinetic analysis, UV/VIS measurements and X-ray crystallography and confirmed ex
vivo in tissue homogenates as well as in vivo in mice. The results of this study are definitely useful for
the design of further selective inhibitors of the two MAO isoforms.
3. A New Lead in the Combat Against the Multi-Drug Resistant Mycobacterium Abscessus
Highlighted by Jean Jacques Vanden Eynde
Mycobacterium abscessus is a nontuberculous ubiquitous pathogen responsible for different kinds
of opportunistic infections, including pulmonary attacks and skin and soft tissues diseases. The species
is resistant to most antibiotics and disinfectants, and many treatments require the use of an association
of multiple drugs. In a recent study, de Ruyck et al. [2] focused their attention on the design, synthesis,
and evaluation of piperidinol-containing molecules (Figure 1) that target the flippase activity of the
mycolic acid transporter MmpL3. They have demonstrated that such an inhibition can result directly
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in the death of the pathogen. It is noteworthy that it could also be exploited in order to create
synergetic effects by facilitating penetration of other substances (i.a. β-lactams) through the wall of
the mycobacterium.
Figure 1. Representative example (PIPD1) of a piperidinol-containing molecule evaluated by de Ruyck et al. [2].
4. New InhA Inhibitors Provided by Fragment-Based Drug Design
Highlighted by Josef Jampilek and CongBao Kang
Fragment-based drug design (FBDD), despite its youth, has provided marketed drugs and others
in clinical trials. It has become an effective strategy for designing lead compounds [3]. The library used
in FBDD contains several thousand fragments and is still growing [4]. FBDD usually includes three
steps: fragment screening, confirmation and growth. A recent study by Sabbah et al. has shown the
application of FBDD to the design of original inhibitors of Mycobacterium tuberculosis InhA, which is an
important target for tuberculosis. Differential scanning fluorimetry was used to screen a library of
800 fragments, and 18 hits were identified. NMR and X-ray methods were used to confirm the identified
hits. The FBDD approach led from 3-trifluoromethylcinnamic acid to potent InhA inhibitors based
on the N-[3-(aminomethyl)phenyl]-1-benzothiophene-2-sulfonamide scaffold with submicromolar
IC50 values [5]. Although the real minimum inhibitory/bactericidal concentrations, the potential of
the compounds to generate resistant/cross-resistant strains, the stability, and the ADME properties of
the compounds should be investigated, this study demonstrated that FBDD is helpful for developing
new inhibitors of a well-studied enzyme using a routine strategy, while careful and rational chemical
design is required.
5. Combined Modulation of Farnesoid X Receptor and Target Genes: A Promising Therapeutic
Strategy in Non-Alcoholic Steatohepatitis
Highlighted by Arduino A. Mangoni
Novel, highly effective therapeutic strategies are urgently needed for the management of
non-alcoholic steatohepatitis (NASH), an increasing cause of chronic liver failure worldwide [6].
Chianelli et al. report the synthesis of a series of non-bile acid farnesoid X receptor (FXR)
agonists based on a tricyclic dihydrochromenopyrazole core [7]. In particular, compound 1,
4-[(N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl]benzoic
acid exhibited partial FXR agonistic activity in vitro and FXR-dependent gene modulation in vivo.
These effects were associated with a favorable pharmacokinetic profile in rodents, particularly,
high bioavailability, moderate volume of distribution and clearance, and short half-life. Furthermore,
in an insulin-deficient murine NASH model, treatment with compound 1 caused a significant
dose-dependent reduction in parameters of liver steatosis, inflammation and fibrosis. After the
successful completion of Phase 1 studies in healthy volunteers, compound 1 is currently being
investigated in Phase 2 studies in patients with NASH. Pending the results of such studies,
the available evidence suggests that the combined modulation of the farnesoid X receptor and target
genes might represent a promising therapeutic strategy for NASH.
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6. Cyclodextrins as a Potent Tool for Fighting Multiple Viral Infections
Highlighted by Paola Fossa and Rafik Karaman
Viral infections kill millions of people and, especially now, the need for new antivirals is
great. Unfortunately, all virucidal molecules described to date are strongly cytotoxic, limiting their
therapeutic application in several patient types or determining severe side effects. Cyclodextrins (CD)
are naturally occurring glucose derivatives with a rigid cyclic structure, consisting of alpha (1–4)-linked
glucopyranoside units. Recent work by Stellacci and Tapparel [8] showed that the team successfully
engineered novel modified entities utilizing cyclodextrins. These entities attract viruses before breaking
them down on contact, thus causing destruction of the virus and combating the infection. The novel
entities are CDs with a sulfonated alkyl chain (Figure 2), representing a new class of non-toxic,
broad-spectrum, biocompatible and virucidal drugs.
Figure 2. Structure of the modified cyclodextrins.
This new development has the potential to derive effective treatments of herpes simplex,
hepatitis C, HIV, respiratory syncytial virus, and Zika virus. Undoubtedly, the modified CDs
may represent a very interesting therapeutic opportunity to be fully investigated.
7. Probing Amyloid Oligomers is Key to Solving the Neurodegeneration Puzzle
Highlighted by Andrea Trabocchi and Peter J. H. Scott
Many neurodegenerative disorders (NDs) are characterized by misfolding, aggregation,
and accumulation of amyloid proteins. Accumulating amyloid deposits cause loss of cellular
function and synaptic connections, brain damage and eventual death. Reflecting this, there has been
significant interest in using amyloid deposits as an imaging biomarker to improve our understanding
of mechanisms underpinning NDs [9]. Thioflavin T (ThT) is a fluorescent dye that has been used
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extensively to study amyloid fibril formation and was also the inspiration for development of the
prototypical amyloid PET radiotracer [11C]Pittsburgh Compound B.
However, recent studies suggest that the small soluble oligomers arising during fibril formation
are actually the toxic and pathogenic form of the misfolded protein, rather than the deposits
themselves [10]. Unfortunately, poor photophysical and binding properties of ThT limit its use to study
oligomers, and next-generation probes enabling the detection of amyloid oligomers are urgently needed.
To address this, Needham et al. have developed Thioflavin X (ThX, Figure 3) [11]. ThX displayed 5- and
7-fold increases in brightness and affinity, respectively, resulting in enhanced detection of structural
differences in early oligomeric species not observed via traditional ThT imaging.
Figure 3. Pathway of amyloid fibril formation starting from monomeric proteins and the common
cross-β sheet motif of amyloid fibrils to which benzothiazole salts bind. The binding of ThX to the fibrils
restricts the rotation around the C—C bond resulting in a fluorescence turn-on response. Reprinted from
Ref [11]—published by the Royal Society of Chemistry.
8. Tyrosyl-DNA Phosphodiesterase 2 as a Novel Target to Enhance the Efficacy of
Topoisomerase II Poisons
Highlighted by Jóhannes Reynisson
The mechanism of action of many anticancer drugs in clinical use is based on damaging DNA due
to the rapid growth of tumor cells. These include topoisomerase II (TOP2) poisons such as etoposide
and mitoxantrone, which trap the TOP2-DNA cleavage complexes, resulting in apoptosis of the cancer
cells. However, the repair enzyme Tyrosyl-DNA phosphodiesterase 2 (TDP2) can undo the trapped
TOP2-DNA complexes, thus counteracting the effect of the TOP2 poisons, allowing the cancer cells to
survive and develop resistance to chemotherapy. Recently, a report on an improved TDP2 inhibitor
ZW-1288 (Figure 4) with low nanomolar activity was released [12]. This ligand is a deazaflavin
derivative and potentiates etoposide and mitoxantrone in prostate, leukemia and lymphoma cancer
cells, whilst expressing weak cytotoxicity. This demonstrates that inhibiting TDP2 with a drug-like
small molecule is possible making this enzyme a very promising therapeutic target [12].
Figure 4. The molecular structure of ZW-1288.
Molecules 2020, 25, 2968 7 of 22
9. Proteostasis Network: A New Paradigm for Drug Discovery?
Highlighted by Simona Rapposelli
Oxidative stress is frequently addressed as the main cause of aging. However, different processes
have been identified that contribute significantly to the onset of neurodegenerative diseases (NDDs),
such as the progressive inefficiency of the proteostasis network [13]. Indeed, among the dysfunctional
mechanisms occurring with aging, two protein degradation systems, the ubiquitin–proteasome system
(UPP) and the autophagy–lysosome pathway (ALP) are being impaired. Therefore, the development
of innovative and multivalent therapies aimed at sustaining proteome balance is a challenging strategy
to identify drug treatments for chronic and disabling diseases or for aging prevention. To date,
natural compounds have been recognized as multifunctional molecules capable of influencing the
stability of the proteome [14], thus representing a valid starting point to design and synthesize new
modulators of the proteostasis network.
10. The Fascinating Perspective of Material Science: Precise Embolization in Tumor Vessels
Through Peptide-Based Nanoparticles
Highlighted by Stefania Galdiero
The development of cancer therapeutic strategies based on angiogenesis attracts great interest
in biomedicine and biotechnology research and could lead to novel materials having great potential
in clinics. Zhang et al. [15] prepared an embolus inside a tumor’s blood vessels to block them,
through mimicking laminin fibrillogenesis, specifically and highly efficiently. This strategy resulted in
the blockage of the tumor vessels and in a higher inhibition of tumors. In particular, the development
of dual-responsive peptide-based nanoparticles made of a fibrillation sequence, a pH-responsive
sequence and a targeting sequence is reported. The peptide nanoformulations are delivered to blood
vessels in the tumors where the microenvironment enables formation of the fibrous network, which
captures the red blood cells forming occlusions specifically in the tumor blood vessels and inhibiting
the growth of the tumor. A biomimetic and promising approach to attack tumor cells and cause
tumor cell death was developed, which suggests that material science may be exploited for in-situ
construction of therapeutic agents for disease treatment.
11. Promising Anti-Leishmania Compounds in the Telluride Sulfonamide Series
Highlighted by Jean-Yves Winum
Leishmaniasis is a neglected parasitic infection that causes skin or visceral lesions and can
be fatal if left untreated. Due to the emergence of resistant parasites, there is an urgent need to
find new targets and to develop more effective and less toxic drugs. Leishmania donovani chagasi
β-carbonic anhydrase (LdcCA) is playing a key role in the growth and virulence of the parasite; thus,
specific LdcCA inhibitors could help fighting this disease more effectively. [16] Angeli and colleagues
have reported the discovery of substituted aryl-benzyl telluride compounds, bearing a sulfonamide
moiety. These compounds displayed nanomolar inhibitory activity against LdcCA. One of the best
inhibitors showed high antileishmanial activity, displaying (i) a selectivity index over 300-fold higher
for the L. infantum axenic amastigotes over THP1 cells and (ii) a selectivity up to 50 times higher than
edelfosine against infected macrophages. In-vitro and in-vivo toxicity experiments have highlighted
the innocuity of this compound. [17] This study provides new directions for the design and subsequent
development of drug candidates targeting the carbonic anhydrase of Leishmania or more generally of
other protozoan parasites.
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12. New Insight in Fak Inhibitors
Highlighted by Chiara Brullo
Fak is a cytoplasmic protein tyrosine kinase overexpressed and activated in different solid cancers.
It has been proposed as a potential target in cancer therapy, particularly in a metastatic phase. Zhao et al.,
miming the bioactive conformation of the well-known diaminopyrimidine motif and using a cyclization
strategy, synthesized a large series of 7H-pyrrolo[2,3-d]pyrimidines as Fak inhibitors. Very recently,
they obtained new 2,7-disubstituted-thieno[3,2-d]pyrimidine compounds by isosteric replacement
of a pyrrole nucleus by a thiophene one [18], the most relevant being 1 (Figure 5), which showed
an IC50 value of 28.2 nM in an enzymatic assay and displayed stronger potency than the reference
compound TAE-226 in different biological assays.
As found in a docking study, compound 1 is anchored to the hinge region by double-dentate
hydrogen bonds of pyrimidine nitrogen and aniline NH to the hinge region, whereas the o-methoxyl
group is involved in the hydrogen bond with Asp564 of the DFG motif (Asp-Phe-Gly). Furthermore,
the water-soluble “tail” of the piperidine moiety interacts with Cys427, confirming its important role in
enzymatic inhibition. For all these reasons, this compound could be a promising lead for Fak-targeted
anticancer drug discovery.
Figure 5. Chemical structure of the lead compound in the work by Zhao et al. [18].
13. Tackling Coronas with EIDD-2801 Pills?
Highlighted by Katalin Prokai-Tatrai
The small molecule β-d-N4-hydroxycytidine (NHC) is a ribonucleoside analogue that inhibits
viral RNA genome replication and is effective against a variety of viruses, including the cause of
the current pandemic: coronavirus disease 2019 (COVID-19). NHC’s 5′-isopropyl ester prodrug,
identified as EIDD-2801, was designed to improve pharmacokinetics and oral bioavailability in
humans and nonhuman primates. It has recently been reported [19] that, when used as a prophylactic,
oral administration of EIDD-2801 resulted in a significant viral load reduction and improved pulmonary
function in mice infected with severe acute respiratory syndrome CoV (SARS-CoV) or Middle East
respiratory syndrome CoV (MERS-CoV). Additionally, the weight loss of the experimental animals also
markedly decreased. When given as a treatment within 12 or 24 h post-infection, the degree of lung
damage could also be reduced. This window of therapeutic opportunity is expected to be significantly
longer in humans. Overall, EIDD-2801 pills hold promise for not only the treatment of COVID-19
patients today but also against new CoVs that may emerge in the future.
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14. Developing Efficient Mutant GTPase KRASG12C Inhibitors: Are We Ready for Mutant KRAS Yet?
Highlighted by Arun K. Sharma
KRAS, a key regulator of signaling pathways that cause cells to proliferate and differentiate,
is a frequently mutated oncogene in human tumors, and G12C is the most common KRAS
mutation in lung adenocarcinoma. Many efforts to develop KRASG12C-specific inhibitors are currently
underway—AMG510 (Amgen) and MRTX849 (Mirati/Array) are in clinical trials. Kettle et al. [20]
further optimized covalent allosteric inhibitors of the mutant GTPase KRASG12C through conformational
locking of a piperazine−quinazoline motif and linker modification and introducing a methyl group
to the piperazine, leading to identification of a potent KRASG12C inhibitor with high selectivity,
improved drug-like properties and excellent in-vivo efficacy. Although more studies would be required
to establish the promise of this compound, this is a significant step forward in designing KRASG12C
inhibitors. However, a recent report [21] suggests that resistance is inevitable for KRASG12C inhibitors
since the cancer cells develop a heterogeneous response to the inhibitors and bypass inhibition by
producing new active KRASG12C that does not bind the inhibitor, indicating that the challenge to
develop efficient inhibitors and achieve complete responses in the clinic continues.
15. A Senolytic PROTAC Exploits the Restricted Expression Profile of CRBN to Lose Toxicity
Associated with Its Parent Inhibitor
Highlighted by Matthieu Schapira
PROTACs are heterobifunctional molecules that recruit an E3 ligase to a target protein, leading to
proteasomal degradation of the target. This novel modality is expected to extend the boundaries
of the druggable genome [22]. He et al. have now established an additional benefit of PROTACs:
the authors exploit the expression profile of the recruited E3 ligase to inhibit the target in tissues where
it is pathogenic, while sparing it in tissues where it is beneficial [23].
Senolytics are compounds that selectively kill senescent cells implicated in age-related diseases
such as osteoarthritis or cardiovascular and neurodegenerative diseases. ABT263, a protein interaction
inhibitor that targets the anti-apoptotic proteins Bcl-xl and Bcl-2, is one of the most potent senolytics,
but has unacceptable on-target toxicity, as Bcl-xl inhibition induces platelet apoptosis, resulting in
severe thrombocytopenia. In an elegant work, He et al. have developed a PROTAC derived from
ABT263 that recruits the E3 ligase CRBN to degrade Bcl-xl. Because CRBN is expressed in senescent
cells but not in platelets, the PROTAC conserved the senolytic activity of ABT263 but lost its toxicity.
16. Possibility to Use Interleukin Itself for Treatment—IL-37 as an Example
Highlighted by Yasu-Taka Azuma
Up to now, more than 40 kinds of interleukins have been reported, and most of them induce
inflammation. Therefore, until now, most of the therapeutic applications of interleukins have focused
on blocking the action of interleukins using neutralizing antibodies. However, some interleukins,
typically IL-10, have been found to have anti-inflammatory effects. Ballak et al. have reported that IL-37,
which is an anti-inflammatory interleukin itself, has therapeutic potential [24]. They investigated the
effectiveness of IL-37 treatment for improvement of physiological function in the elderly. Recombinant
IL-37 treatment to old mice increased vascular endothelial function and endurance exercise capacity
and improved whole-body insulin sensitivity and glucose tolerance. In addition, IL-37 has also been
reported to show anti-inflammatory effects in patients with arteriosclerosis [25]. This interleukin
therapy has further expanded the options for treating various diseases.
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17. RNA-Based Nanoconstructs for Targeted Delivery of Paclitaxel to Breast Cancer: The Road to
Drug Efficacy and Safety
Highlighted by Laura Cerchia
Targeted delivery of chemotherapy enhances the anticancer activity of the drug and limits side
effects on healthy organs by increasing its concentration at the tumor site while dispensing lower absolute
doses of the drug. Consequently, the development of novel cancer-targeted drug delivery systems
represents one of the hottest areas of modern cancer research. Recently, Guo et al. [26] constructed
a smart RNA-based multifunctional nanovector for targeted delivery of paclitaxel, whose use in
the clinic is limited by scarce bioavailability and severe toxicity, to triple-negative breast cancer,
by using aptamers for guaranteeing tumor targeting. Specifically, a ”X”-shaped RNA four-way
junction nanostructure with ultra-thermodynamic stability was assembled with the extraordinary
loading capability of twenty-four paclitaxel molecules as the prodrug. The intravenous injection of
the construct, equipped with a previously validated and high efficacious anti-EGFR aptamer, in mice
bearing orthotopic tumors greatly inhibited breast cancer growth. Further, nanoconstructs exhibited
low/undetectable toxicity or immune responses in mice. Improving the transport of the drug to the
tumor, by specific drug delivery platforms, will open up the possibility of accessing lower-cost and
highly effective therapies.
18. New Insights into Mechanisms for Allosterically Modulating the Kappa Opioid Receptor
with Nanobodies
Highlighted by Mariana Spetea
G-protein-coupled receptors (GPCRs) represent the most-targeted class of druggable proteins in
the human genome [27]. The kappa opioid receptor (KOR) has emerged as an important therapeutic
target for the treatment of pain and neuropsychiatric conditions. As a GPCR, KOR rapidly interconverts
between multiple states, though the ability to visualize them is limited by a relative lack of suitable
tools. Nanobodies (Nbs) provide a powerful platform to stabilize distinct receptor conformations.
Che et al. [28] have demonstrated, via X-ray crystallography, a nanobody-targeted allosteric binding site
of KOR, by which Nb6 stabilizes a ligand-dependent inactive state and Nb39 stabilizes an active-like
state. They have shown how these two state-dependent nanobodies can provide real-time reporting of
ligand stabilized states in cells in situ. Analysis of the KOR–Nb6 complex revealed a unique nanobody
binding interface by which Nb6 negatively allosterically modulates KOR. The observation that this site
can be transferred to other GPCRs to provide an engineered and functional allosteric site was also
remarkable. Furthermore, given that Nb6 and Nb39 interact with distinct states of KOR, they can be
used as biosensors to detect ligand-stabilized states in real time in living cells.
19. Is the Role of LMW Heparin in COVID-19 Infection Really Only Antithrombotic or Not?
Highlighted by Giangiacomo Torri
My answer to the question is no. It is well established that polyanionic molecules exhibit antiviral
activities. Concerning heparin, the most relevant polyanionic macromolecule expressed by mammalian
organisms, in the literature there are more than 3500 articles stating its antiviral activities with respect
to different kinds of viruses. Among the 62 articles concerning SARS-CoV-2 and heparin, a basic
research study by researchers experienced in glycosaminoglycans and proteins has demonstrated that
a physical–chemical interaction between heparin and the viral protein occurs [29].
The current pandemic took us by surprise, and we found ourselves mostly unprepared to
manage it in terms of experience and availability of adequate drugs, despite numerous studies on
non-anticoagulant heparin derivative candidates. It is necessary to pursue a larger interchange between
basic research, drug development and clinical knowledge. The goal is to minimize the dichotomy
between clinical world and laboratory research.
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20. Identification of Small Molecules Targeting Zika Virus NS2B-NS3 Protease via
Fragment-Based Drug Discovery (FBDD) Approach
Highlighted by Simona Collina
In their recent publication, Quek et al. [30] have reported the successful application of a
fragment-based drug discovery (FBDD) approach to identify small molecules targeting Zika virus
(ZIKV) protease. ZIKV is a mosquito-borne flavivirus, which recently emerged as a global health
threat. The viral NS2B-NS3 protease has an essential role in the maturation of viral proteins and
represents an attractive therapeutic target for fighting ZIKV. The major drawback for development of
NS2B-NS3 inhibitors is the negatively charged binding site. With the final aim to identify molecules
with high affinity to the pocket and with drug-like properties, the authors adopted a FBDD approach.
Employing a primary thermal shift assay, a fragment library of 1685 compounds was screened against
the Zika protease, and twenty-two fragments were selected. After co-crystallization experiments,
the X-ray structures of two complexes were successfully solved, showing that both compounds interact
with the same site. These two hits were further characterized by STD NMR studies confirming their
molecular interactions with the target. These fragments can be used as starting compounds for further
growing into more potent inhibitors, thus paving the way for the discovery of novel effective ZIKV
protease inhibitors.
21. Synthesis and Chemical Profile of New HIV-1 Capsid Targeting Peptidomimetic Analogous
of PF74
Highlighted by Athina Geronikaki
The infection and dismantling of T cells engineered by the human immunodeficiency virus
(HIV) induce human acute immunodeficiency syndrome (AIDS). The capsid protein (CA) involved in
HIV-1 possesses a central role in various steps of the cycle of virus replication: in convening the core
of functional capsid, regulating the kinetics of DNA entry and viral core uncoating with multiple
host–factor interactions.
Among all known small molecule chemotypes that target CA, the peptidomimetic PF74 has drawn
particular interest since it exhibits a binding ability to the corresponding pocket. Wang et al. [31]
have provided a thorough chemical optimization of PF74 by synthesizing and evaluating a broad
amount of PF74 analog (Figure 6). Antiviral tests and CA hexamer stability accomplished on these
analogs revealed occasional key pharmacophore aspects, including a phenyl moiety, a halogen
para-substitution and a tiny alkyl group at the nitrogen in the aniline region, and the tolerance of
carbon-3 and NH belonging to the indole skeleton for adjustment.
Figure 6. General structure of synthesized compounds.
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22. Let Cancer Cells Trip Themselves Up
Highlighted by Alfonso T. Garcia-Sosa
Many drug design efforts towards cancer therapy have concentrated on stopping the cellular
processes of diseased cells. A new approach by Schulze et al. [32] overrides the spindle assembly
checkpoint with small molecule inhibitors of MPS1 kinase, so that cancerous cells are allowed to
progress to cell division with errors and mutations in their DNA in a so-called mitotic catastrophe.
This has the effect of killing the cells at a later stage. Two separate chemical series were optimized with
X-ray studies leading to two highly potent clinical candidates with favorable in-vivo PK properties:
triazolopyridine BAY 1161909 and imidazopyridazine BAY 1217389. These ATP-competitive inhibitors
make use of differently shaped binding pockets of MPS1 as well as different interactions with the
protein. They are also synergistic in combination with the chemotherapy drug paclitaxel, which acts
by interference with the normal function of microtubules during cell division. These compounds are
the first MPS1 inhibitors to enter Phase I clinical trials, doing so with a novel mechanism of action.
23. Studies on SARSCoV-2 Spike Glycoprotein Open Doors for Covid-19 Drug Discovery
Highlighted by M. Helena Vasconcelos and Maria Emília Sousa
Three highly pathogenic zoonotic coronaviruses emerged recently: SARS-CoV in 2003, MERS-CoV
in 2012, and SARS-CoV-2 in 2019. Coronavirus entry into host cells is mediated by the transmembrane
spike (S) glycoprotein. In this study, Walls et al. [33] demonstrated that SARS-CoV-2 S uses ACE2
to enter cells. In addition, cryo-electron microscopy structures of the SARS-CoV-2 S glycoprotein
revealed the presence of multiple conformational states of the SARS-CoV-2 S ectodomain trimer,
providing important information for the discovery of vaccines and drugs to inhibit viral entry into
cells. Finally, these authors observed a sequence and conformational conservation of the S protein
fusion peptide regions between two coronaviruses (SARS-CoV-2 and SARS-CoV), putting forward
the idea that infection by one of these two viruses could cause production of antibodies which might
cross-react and neutralize both viruses as well as other related coronaviruses. Indeed, their results
indicated that SARS-CoV S murine polyclonal antibodies potently inhibited SARS-CoV-2 S-mediated
entry into cells.
24. With or Without ssDNA Genome, Pf4 Filamentous Phage Promotes the Stability of
P. Aeruginosa Biofilm Formation and Consequently Increases Protection Against Antibiotics
Highlighted by Ivan Kosalec
Opposite to the well-known predation effects of bacteriophages on bacteria, filamentous phages
express an interesting evolution-driven symbiotic relationship. Filamentous phages contain an ssDNA
genome and very long and thin helically packed capsids. They do not harm the bacterial host, and,
after egressing from the host, these phages symbiotically help bacteria to survive and to form more
protected biofilms, especially during Pseudomonas aeruginosa infection [34,35]. The recent work of
Tarafder et al. [36] has provided deeper insights into Pf4 filamentous phage and P. aeruginosa biofilm
interactions, showing that Pf4 phages with ssDNA and capsid shell form protecting liquid shields
around P. aeruginosa cells in biofilms. Removing the genome, Taragder et al. [36] found that phages
with empty protein-structure capsid shells called “ghosts” formed liquid crystals around bacterial
cells still protecting bacteria from antibiotic treatment. These observations have a great impact on
bacteriophage–P. aeruginosa cell interactions in biofilms and reveal a more complex influence of
Pf4 phages. Our strategy to modulate these effects on biofilms caused by P. aeruginosa must change
as well.
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25. An NMR Drug Screening Approach in Human Cells as a New Tool for Drug Potency
Early Assessment
Highlighted by Tiziano Tuccinardi and Iola F. Duarte
A classical drug development workflow usually starts by screening the activity of multiple ligands
against the selected target. Once a hit is identified, its chemical structure is used as a starting point for
chemical modifications to improve potency and selectivity. However, promising candidates showing
good performance in vitro often lack in-vivo activity, due to low membrane permeability or poor
intracellular binding selectivity. Banci et al. reported an innovative experimental protocol to screen
ligands in living human cells by “intracellular protein-observed” NMR spectroscopy, without requiring
enzymatic activity measurements or other cellular assays. The method proposed is based on the
observation and spectral deconvolution of 1H signals arising from free and ligand-bound fractions
of the target macromolecule. Signal areas are used to build quantitative dose and time-dependent
ligand binding curves, from which kinetic and thermodynamic parameters linked to cell membrane
permeability and binding selectivity are retrieved [37]. Such an approach, applied in this work to
carbonic anhydrase but extendable to other NMR-observable intracellular targets, represents a useful
means to predict drug potency at an early stage of the development process.
26. Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance
Highlighted by Jorge A. R. Salvador
Proteasome inhibitors (PIs), particularly bortezomib, have significantly improved the overall
survival and quality of life of multiple myeloma (MM) patients. However, cancer resistance and relapse
remain major difficulties in expanding the clinical utility of PI drugs.
Hao Fang et al. [38] have designed and synthesized a novel series of peptide boronate derivatives
as dual inhibitors targeting both histone deacetylases (HDACs) and proteasomes to address the
resistance of bortezomib. The most potent inhibitors, ZY-2 (Figure 7) and ZY-13, showed excellent
inhibition against proteasome and good selectivity against HDACs.
Specifically, ZY-2 also exhibited good antiproliferative activities on the MM cell lines RPMI-8226,
U266, and KM3 (IC50 values of 6.66, 4.31, and 10.1 nM, respectively). In addition, ZY-2 showed more
potent antiproliferative activities against the bortezomib-resistant MM cell line KM3/BTZ compared
with bortezomib (IC50 values of 8.98 vs. 226 nM, p < 0.01). Moreover, ZY-2 also exhibited excellent
potency in cell apoptosis induction and cell cycle arrest and decreased the levels of Sp1 and HDAC1 at
low concentrations in the bortezomib-resistant MM cells.
Figure 7. Chemical structure of ZY-2.
27. BRAF-V600E Degraders: A New Weapon Against Melanoma
Highlighted by Massimo Bertinaria and Maurizio Pellecchia
The activating mutation V600E in the kinase BRAF is a major driver in several human cancers.
BRAF-V600E produces a constitutively active kinase, which signals the expression of proliferation
and survival genes in cancer cells [39]. BRAF-V600E inhibitors, such as vemurafenib, dabrafenib and
encorafenib, are currently clinically approved for the treatment of BRAF-V600E-driven melanoma.
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One major drawback of these inhibitors, however, is represented by their paradoxical induced activation
of wt-BRAF and concomitant activation of ERK signaling. Hence, in a potentially transformative new
approach, Wang et al. have developed proteolysis-targeting chimeras (PROTACs) able to promote a
selective proteasome-mediated degradation of mutant BRAF-V600E [40]. Two agents were obtained
by linking vemurafenib to thalidomide using a short spacer, and by linking BI882370 (a newer and
more selective BRAF-V600E inhibitor) to pomalidomide using a PEG-based spacer. The new agents
are able to induce degradation of BRAF-V600E at nanomolar concentrations and inhibit the growth
and viability of A375 melanoma cells. Most importantly, the agents do not promote degradation of
wild-type BRAF, hence sparing non-neoplastic human cells.
28. Target-Guided Synthesis of Noncanonical DNA-Binding Transcriptional Modulators
Highlighted by Jussara Amato
G-quadruplex and i-motif are four-stranded noncanonical nucleic acid structural arrangements.
Recent evidence suggests that these DNA structures exist in living cells and are involved in several
cancer-related processes, like the transcriptional regulation of proto-oncogenes, thus representing an
attractive target for anticancer drug discovery. Considering the dynamic nature of DNA structures,
the development of small molecules that can bind to them with high affinity and selectivity has
always been challenging and time consuming. Dash et al. have reported an innovative example of
a target-guided synthetic approach, using DNA-immobilized magnetic nanotemplates and an array
of azide and alkyne fragments, in which the active site of the biological target controls the assembly
of the best binding fragments [41]. The in-situ-generated lead compounds can be easily isolated by
simple magnetic decantation, and DNA templates can be recovered and recycled. The identified
small molecules effectively showed high affinity and specificity for the target, as well as the ability to
modulate gene expression. This approach might pave the way to in-situ development of transcriptional
modulators for therapeutic interventions.
29. The Crystal Structure of the SARS-CoV-2 Main Protease: New Hopes to Fight a
Threatening Disease
Highlighted by Giulio Rastelli
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the new virus responsible
for the COVID-19 outbreak, is posing a real threat to global health. Jin et al. [42] have described
the crystal structure of the main protease (Mpro) of SARS-CoV-2 (Figure 8), an essential enzyme
of the viral life cycle. The authors firstly developed a fluorescence resonance energy transfer assay
compatible with high-throughput screening, then solved the crystal structure of SARS-CoV-2 Mpro in
complex with the Michael acceptor inhibitor N3 at 2.1 Å and 1.7 Å resolutions (PDB codes 6LU7 and
7BQY, respectively). The ligand binds in the substrate cleft by adopting an extended conformation
(Figure 8); it is covalently bound to catalytic cysteine and establishes several hydrogen bonds and
hydrophobic contacts. Remarkably, high-throughput screening of a library of about 10,000 compounds
identified six ligands (disulfiram, carmofur, ebselen, shikonin, tideglusib and PX-12) able to inhibit the
SARS-CoV-2 protease with micromolar IC50, with ebselen and N3 also showing antiviral activity.
Without doubt, the availability of this crystal structure will greatly support the rational
identification of drug leads and/or repurposed drugs for the treatment of COVID-19, for which
effective therapeutics are still lacking.
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Figure 8. Crystal structure of the SARS-CoV-2 main protease in complex with ligand N3 (PDB code 7BQY).
30. Stalobacin I: The Newest Member of the Remarkable Family of Peptide-Based Antibiotics
Highlighted by Paula A. C. Gomes
Resistance to antibiotics currently available in clinics is reaching alarming levels, and can affect
anyone, of any age, gender or socio-economic status, in any region of the world. Of particular concern
are the so-called ESKAPE pathogens, multi-drug resistant (MDR) strains of Enterococcus faecium,
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,
and Enterobacter bacteria that are major players in nosocomial infections. When current antibiotics fail
to mitigate severe and life-threatening infections, “last-resort” options come into play, including use
of the well-known natural lipocyclopeptides daptomycin and colistin, or the more recent synthetic
glycopeptide telavancin [43]. This prominent role of peptide-based antibiotics in the battle against
MDR infections has been consolidated over recent years by the discovery of other natural peptides
with non-canonical structures, like teixobactin [44] or lungdunin [45]. Stalobacin I, a lipopeptide now
identified by Matsui et al., comes to enrich the portfolio of peptide-based antibiotics with potent action
against MDR Gram-positive bacteria [46]. Hopefully, similar success will soon emerge regarding
discovery of as-yet-elusive alternatives to polymyxins or colistin as peptide-based antibiotics to fight
MDR Gram-negative bacteria.
31. Are We Now One Step Closer to the Discovery of new Antibiotics or Overcoming Their
Resistance with Artificial Intelligence?
Highlighted by Rita C. Guedes and Jean-Marc Sabatier
Antibiotic-resistant bacteria have risen sharply and are a major challenge in drug discovery.
To address this challenge, Collins et al. [47] have applied a deep learning approach based on neural
network training to identify new chemotypes with putative antibacterial activity. Their combined
approach to identify potential lead compounds consisted of the training of a deep neural network
model to predict growth inhibition of E. coli (2335 molecules), which was then applied to the screen
of multiple chemical libraries (>107 million molecules). Selected compounds (the best ranked as
structurally “unique” compared with other antibiotics and devoid of apparent toxicity) were then
tested against bacterial growth. Among other potential compounds, the c-Jun N-terminal kinase
inhibitor SU3327 (halicin) was identified as a potent E. coli growth inhibitor. This work proves the
importance of the use of machine learning in our drug discovery pipelines to expand conventional
chemical space.
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32. Design and Synthesis of Oral Bioavailable Chromone Derivatives as Novel Selective
BRD4 Inhibitors
Highlighted by Ana Estévez-Braun
BET family proteins, especially BRD4, represent a promising epigenetic target for human diseases,
such as cancers, inflammations, CNS disorders, heart failure, and HIV infection. A series of compounds
based on the chromone core were designed and obtained through a scaffold hopping approach.
Two of them, ZL0513 and ZL0516 (Figure 9), displayed nanomolar binding affinity (IC50 67–84 nM)
with BRD4 BD1 [48]. Their binding modes were validated by the cocrystal structure of ZL0516
in complex with human BRD4 BD1. These compounds also showed significant in-vivo efficacy
in a murine model of TLR3-induced acute airway inflammation. Finally, pharmacokinetic studies
revealed that both compounds are orally available, indicating their potential as therapeutic agents in
inflammatory diseases.
Figure 9. Structures of ZL0513 and ZL0516.
33. Aptamers as a Therapeutic Tool Against Prion Diseases
Highlighted by Bruno Pagano
Prion diseases, also known as transmissible spongiform encephalopathies, are fatal
neurodegenerative disorders affecting humans and animals. An innovative and promising therapeutic
approach is based on the use of nucleic acid aptamers to block the hallmark event in the prion diseases,
i.e., the conversion of prion protein into an abnormal form. Starting from a previously identified RNA
aptamer, Mashima et al. have rationally developed a new aptamer that exhibited very high anti-prion
activity [49]. Rationalization of the high anti-prion activity was also provided on the basis of RNA
structure determination. The achievement of an IC50 value of 100 nM represents a substantial advance
that has opened the realistic possibility of applying these nucleic acid molecules for therapeutic use.
The development of drugs against prion diseases is long overdue. These results may pave the way to
the development of new, powerful tools against diseases lacking effective therapy.
34. A Newly Designed γ–Lactam-Siderophore Conjugate Shows Significant Antibiotic Activity
Against Multidrug-Resistant Gram-Negative Bacteria
Highlighted by Stefano Mangani
The concept of using the siderophore importers present in Gram-negative bacteria to facilitate the
intake of antibiotics into the periplasmic space [50] has been applied to the development of a new compound
endowed with interesting activity against multidrug-resistant (MDR) bacteria. Goldberg et al. [51]
have reported the design, synthesis, structural characterization and antimicrobial activity of a novel
pyrazolidinone antibiotic containing a dihydroxyphthalimide siderophore mimetic. The compound,
dubbed YU253434, contains the 2-(2-aminothiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetamido
moiety of ceftazidime linked to the pyrazolidinone nucleus, which in turn bears a dihydroxyphtalimide
acting as a siderophore mimic (Figure 10). YU253434 acts a covalent inhibitor of PBPs (Penicillin Binding
Proteins) by binding to the catalytic serine residue as shown by the X-ray crystal structure of its complex
with PBP3.
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Figure 10. Structure of YU253434.
YU253434 is stable with respect to β-lactamases of all classes. Its MICs against clinical isolates
of relevant MDR bacteria compare favorably with those of β-lactam antibiotics used in clinics.
The structure of the YU253434 bound to PBP3 provides hints for further optimization of this
promising compound.
35. Tackling SARS-CoV-2: Key Hints for Structure-Based Design of Broad-Spectrum Inhibitors of
3CL Protease
Highlighted by Rino Ragno, George Kokotos, Margherita Brindisi and Florenci V. González
The COVID-19 pandemic caused by SARS-CoV-2 has generated an unprecedented health
emergency worldwide. The development of broad-spectrum antivirals useful for future outbreaks
of pathogenic coronaviruses is of absolute priority. Proteolytic enzymes, essential for producing
mature virions, represent attractive targets for drug development. One of them is the SARS-CoV-2
chymotrypsin-like protease (3CLpro), a protease utilizing a Cys–His catalytic dyad for its hydrolytic
activity. In their quest for novel broad-spectrum 3CLpro inhibitors (Figure 11), Hilgenfeld et al.
identified compound 1, featuring an α-ketoamide warhead [52]. Based on 1, structure modification led
to new compounds with an extended activity spectrum against coronaviruses, while improving the
drug-like profile [53]. In order to enhance metabolic stability and decrease plasma protein binding,
the P3-P2 amide was embedded into a pyridone ring, and the terminal cinnamoyl portion was replaced
by a tert-butoxycarbonyl group. The X-ray structures of the unliganded SARS-CoV-2 3CLpro and
its complex with an α-ketoamide inhibitor were solved and enabled structure-based drug design.
Compound 2 effectively inhibited the main coronaviruses 3CLpro (SARS-CoV-2, SARS-CoV and
MERS-CoV) with an average IC50 of 0.79 µM and exhibited promising antiviral potency in cell-based
assays, with associated improved half-life and favorable lung tropism.
Figure 11. Structure of α-ketoamide-based broad-spectrum 3CLpro inhibitors 1 and 2.
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36. Drug Discovery and Central Nervous System Diseases: Neuroinflammation as a Step Forward
Highlighted by Fernanda Borges
Central nervous system (CNS) diseases are a large group of neurological disorders with
heterogeneous clinical and pathological expressions. The intricate network of regulatory mechanisms
remains largely elusive, and, to date, no specific factor has been identified as a direct cause. Furthermore,
the existing drugs in therapy are only palliative and fail to modify disease progression.
Identifying and validating novel and druggable CNS targets remains a hot topic in drug
discovery, in particular those involved in neuroinflammation. Interestingly, the prostanoid EP2
receptor has been associated with neuroinflammation and neurodegeneration in CNS diseases.
In this context, the work of Thota Ganesh’s research team reports the discovery of new EP2
antagonists, obtained after a lead optimization process. This work describes the improvement of
selectivity and drug-like properties of the brain-permeating lead TG6-10-1. The optimized antagonist,
2-[(4,6-dimethylpyridin-2-yl)amino]-N-[2-(2-methyl-1H-indol-3-yl)ethyl]pyrimidine-5-carboxamide
hydrochloride (TG11-77·HCl), has a higher selectivity index, suitable brain permeability and excellent
water solubility [54].
37. Evaluation of Nonvaccination Preventive Mechanisms to Fight Antibiotic Resistence:
Evidence from Enteropathogenic E. coli Infection
Highlighted by Mariarosaria Miloso
Antibiotic resistance is a crucial problem for human health, and it is fundamental to explore
alternative therapeutic options to treat bacterial infections. Qiu et al., by in-vitro and in-vivo experiments,
demonstrated the effectiveness of a specific reactive peptide to block enteropathogenic E. coli (EPEC)
infection [55]. EPEC infection starts with the attachement of a bacterium to the surface of an
intestinal cell in order to inject Tir protein into the cytoplasm. Tir interacts with Nck adaptor, which,
in turn, allows the interaction of Tir with the Arp2/3 complex involved in actine reorganization and
polimerization. Formation of an actin pedestal is responsible for cell lesions and specific symptoms
of EPEC infection. Nck is an adaptor with different domains, among which the second SH3 domain,
Nck-SH3.2, is specifically involved in Tir interaction. Qui et al. [55] have reported the design of a
synthetic peptide that binds to the Nck-SH3.2 domain at the level of Cys48. This interaction blocks
the Nck binding site for Tir. Consequently, Tir cannot interact with Arp2/3 complex and no actin
reorganization occurs blocking EPEC infection. The reactive peptide, which acts on cells rather than on
the pathogen, may be a promising approach to fighting drug resistance.
38. Glucuronide Prodrug, PEGylation, Albumin Binder, Self-Immolative Linker, and a Potent
Toxin: An Ideal Ensemble for Efficient Tumor Suppression Upon Highly Localized Bioactivation
Highlighted by Jarkko Rautio and Diego Muñoz-Torrero
Zelikin’s group [56] have reported efficient suppression of tumor growth by enzyme prodrug
therapy, which takes advantage of noncovalent albumin binding and, subsequently, delivery of the
prodrug to the tumor as well as the endogenous enzymatic repertoire of the tumor. To this end, a total
of eight glucuronide prodrugs of highly cytotoxic monomethyl auristatin E (MMAE) were engineered,
where a self-immolative scaffold based on o-substituted p-hydroxybenzyl alcohol provided a spacer
between the drug, glucuronide, and either the molecular (e.g., alkyne), macromolecular (e.g., PEGs),
or supramolecular (e.g., trityl (Tr)-PEG) protraction arm. While most prodrugs significantly masked
the toxicity of MMAE and were well tolerated after subcutaneous administration to an MDA-MB-231
ectopic xenograft mouse model, only the Tr-PEG glucuronide prodrug (Figure 12) afforded statistically
significant suppression of tumor growth. The best prodrug could not be predicted from the in-vitro
toxicity screens or in-vivo derived pharmacokinetics parameters, but favorable anticancer effects
correlated only with accumulation of the released payload from the prodrug at the tumor site. This is a
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very useful approach for all modalities of cancer detection, imaging, and treatment relying on enhanced
tumor localization!
Figure 12. Chemical structure and mechanism of the bioactivation of the Tr-PEG glucuronide
supramolecular MMAE prodrug.
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